MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 21.03.2026
Compugen Ltd. Langfristiger Schuldenstrom 2011-2026 | CGEN
Langfristiger Schuldenstrom Jährlich Compugen Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 768 K | 639 K | 600 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 768 K | 600 K | 669 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.56 | 2.13 % | $ 3.74 B |  USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
10.8 M | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.9 | 3.7 % | $ 9.38 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.49 | 9.56 % | $ 397 M |  Britain |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
631 K | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Cabaletta Bio
CABA
|
3.46 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Codiak BioSciences
CDAK
|
2.66 M | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 32.41 | 3.38 % | $ 2.15 B | USA |
 |
Celsion Corporation
CLSN
|
406 K | - | -6.63 % | $ 13.9 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Chimerix
CMRX
|
642 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
1.16 M | - | - | $ 401 M | USA |